A Phase 1 interventional study of HMPL-523 in Healthy, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Hutchmed · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, open-label, randomized, three-period, six-sequence study to evaluate the effect of food (high-fat and low-fat) on the PK of HMPL-523. In this study, 18 healthy Chinese participants are planned to be enrolled, randomized in a ratio of 1:1:1:1:1:1 to one of 6 dosing sequences (see dosing sequence table for details), and administered once per cycle for 3 cycles, with a washout period of at least 7 days. The study consists of a screening/baseline period, a dosing period (three cycles), and a follow-up period.
Screening Period/Baseline Period The trial participants will sign a written informed consent form on a voluntary basis prior to screening. Screening period/baseline period assessment will be completed within 14 days prior to the first dose. At screening/baseline, demographic data, medical history, medication history, allergy history, blood donation history, and participation in clinical trials should be collected, and physical examination, vital sign measurements, 12-lead ECG, infection markers, laboratory tests, pregnancy test , and chest X-ray will be performed.
Trial participants who pass the preliminary screening will be admitted to the study site 3 days prior to the first dose (i.e., 3 days prior to medication of Cycle 1), vital signs examination, urine drug abuse screening, alcohol breath screening will be performed on the day of admission, recent dietary and medication use will be inquired, and pregnancy test will be conducted (only for women of childbearing potential. If the screening examinations and baseline examinations will be conducted on the same day, they can be done once), and the inclusion and exclusion criteria will be further checked.
Only serious adverse events will be collected during screening/baseline period. Dosing Period (3 cycles) The day before the first administration, trial participants passing the screening will be given a randomization number according to the randomization scheme, and assigned to one of 6 dosing sequences in a ratio of 1:1:1:1:1:1. The dosing sequences include ABC, ACB, BAC, BCA, CAB and CBA, and the three dietary conditions are fasting (A), standard high-fat breakfast (B) and standard low-fat breakfast (C). Each participant will receive a single oral dose of HMPL-523 acetate tablets 300 mg (3 tablets × 100 mg) on Day 1 of each cycle in accordance with the dosing sequence. During the study, every effort should be made to ensure that the participant takes the medication according to the study protocol.
Administration Method Fasting (A): Participants will fast for at least 10 hours, have blank blood sample collected, and take the study drug with about 240 mL of water. Except for the water for drug administration mentioned above, water will be deprived from 1 hour pre-dose and 1 hour post-dose. Food will be deprived within 4 hours post-dose.
Standard high-fat breakfast (B) or standard low-fat breakfast (C): Participants will fast for at least 10 hours before the standard high-fat breakfast (B) or standard low-fat breakfast (C), start eating breakfast 30 minutes before dosing, and finish the meal within 25 minutes. After the meal, participants will have blank blood sample collected, and take the study drug with about 240 mL of water exactly 30 minutes from the start of the meal. Water will be deprived from 1 hour pre-dose to 1 hour post-dose, except for the beverages included in the prescribed breakfast and water taken with medication. Food will be deprived within 4 hours post-dose.
During hospitalization, the diet of the participants will be provided by the site. On the day of dosing in each cycle, lunch and dinner (both regular meals) will be served 4 hours and 10 hours after dosing, respectively; at other times, 3 meals will be provided according to the schedule arranged by the site.
The dosing period consists of three cycles, and the scheduled PK blood sampling time points for each participant in each cycle are as follows: within 0.5 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60,and 72 hours post-dose, with a total of 18 collections, and about 3 mL of venous blood will be collected each time. The 4-hour post-dose blood sample must be taken prior to lunch.
After the participants are admitted to the clinical study ward, the vital sign measurements will be performed 1 day pre-dose in each cycle and 3±1 hours post-dose on Day 1 of each cycle. Vital sign measurements, blood chemistry, and hematology will be performed on Day 4 of the each of Cycle 1 and Cycle 2. On Cycle 3 Day 4, the participants will be discharged after vital sign measurements, physical examination, laboratory tests, and 12-lead ECG examination are completed.
Strenuous exercise, alcohol, tobacco, tea, and caffeinated beverages should be avoided during the study. Seville oranges, grapefruits or beverages containing these fruits should be avoided during the study.
Follow-up Period Participants will be followed up to Day 12±2 after the last dose (the day of the last dose is defined as Day 1 of follow-up period). The investigator will collect all (adverse events) AEs and concomitant medications/therapies from the participants during this period through telephone calls (or other means such as text messages). If there are AEs ongoing at follow-up, follow-up will continue until the events return to normal level, abnormal and not clinically significant, baseline level, stable or lost to follow-up, or refusal to visit, etc.
Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.
Drug: HMPL-523
The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.
Drug: HMPL-523
The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.
Drug: HMPL-523
The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.
Drug: HMPL-523
The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.
Drug: HMPL-523
The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.
Drug: HMPL-523
The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.
AUC0-t
Area under the plasma concentration-time curve from time zero to the last time point t where the concentration could be accurately determined
Time frame: up to one months
AUC0-∞
Area under the plasma concentration-time curve from time 0 to infinity
Time frame: up to one months
Cmax
Maximum plasma concentration
Time frame: up to one months
Tmax
Other PK parameters of HMPL-523, such as time to Cmax
Time frame: up to one months
t1/2
Other PK parameters of HMPL-523, such as terminal elimination half-life
Time frame: up to one months
Adverse events rate
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: up to one months
Laboratory tests
Number of participants with abnormal laboratory tests results
Time frame: up to one months
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Jan 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sovleplenib